Media

First patient enrolled in Oncopeptides’ real-world evidence study MARINA in Germany

Vicore Pharma to Host Webcast to Discuss Buloxibutid and the Evolving IPF Treatment Landscape

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

Adcendo ApS Announces Clinical Collaboration and Supply Agreement with MSD to Evaluate ADCE-T02 in Combination with KEYTRUDA® (Pembrolizumab) in a Phase Ib Study in Patients with Advanced Solid Tumors

Oncopeptides signs agreement with Salus for distribution and commercialization of Pepaxti in Central and Eastern Europe

Vicore Pharma to Present at the Jefferies Global Healthcare Conference

HealthCap invests in Neobiomics to support continued growth in neonatal care

Intervacc completes successful evaluation of US strain of strangles pathogen ahead of clinical trials

Hemab Therapeutics Reports First Quarter 2026 Financial Results

Oncopepetides – Bulletin from the Annual General Meeting